ALAMEDA, Calif. , July 31, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the second quarter ended June 30, 2019 , on
ALAMEDA, Calif. , July 24, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, molecular diagnostic tests for the early detection and management of cancer, today announced the appointment of Melinda Griffith to its Board of Directors.
ALAMEDA, Calif. , June 26, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today provided a mid-year update and announced that the Company will require additional time to complete its ongoing CLIA
ALAMEDA, Calif. , June 11, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of lung cancer, today announced that the company will be added to the Russell 2000®, Russell 3000® and Russell Microcap Indexes, effective
Appoints diagnostic industry veteran and current Board member Ronald Andrews, Jr. as Chief Executive Officer Outgoing CEO William Annett to serve as an advisor to the Company Company to host conference call and webcast today, June 6 , at 8:30am EDT ALAMEDA, Calif.
Company presentation scheduled for Wednesday, June 5 at 10:45am EDT ALAMEDA, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced that Chief Executive Officer William
Padma Sundar Appointed Senior Vice President, Marketing and Market Access Dr. Kim Dickinson Appointed Vice President, Clinical Operations ALAMEDA, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection
Results were achieved using blood gene expression biomarkers alone and without the use of clinical parameters Company remains on-track to make DetermaVu™ commercially available in 2H 2019 ALAMEDA, Calif. , May 21, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of
Completes successful Analytical Validation study and initiates CLIA Validation study On track for commercial availability of DetermaVu™ in 2H 2019 Conference Call Today at 4:30 PM EDT ALAMEDA, Calif. , May 14, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of
Company to host conference call and webcast at 4:30pm ET ALAMEDA, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results
On track for commercial availability of DetermaVu™ in 2H 2019 Conference Call Today at 4:30 PM EDT ALAMEDA, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of lung cancer, today reported
Poster presentation and discussion to detail compelling results from R&D Validation study of the Company’s DetermaVu™ liquid biopsy test for the early detection of lung cancer ALAMEDA, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel,
ALAMEDA, Calif. , March 25, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the fourth quarter and year ended December 31,
ALAMEDA, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett , CEO of OncoCyte Corporation , will be presenting at the Cowen and Company 39 th Annual
Company remains on-track for commercial availability of DetermaVu™ Lung in 2H 2019 ALAMEDA, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced the initiation of the
ALAMEDA, Calif. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the closing of an underwritten public offering.
ALAMEDA, Calif. , Feb. 08, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the pricing of an underwritten public offering of 9,333,334 shares of its common
ALAMEDA, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten
Results show 90% sensitivity and 75% specificity, demonstrating best-in-class performance On track for commercial availability of DetermaVu™ Lung in 2H 2019 Results suggest the potential to address a U.S. market opportunity of $4.7 billion Unique immune system interrogation approach may have
Conference call scheduled for Tuesday, January 29, 2019 at 8:30am ET ALAMEDA, Calif , Jan. 28, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today scheduled an announcement and conference call to
FREMONT, Calif. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today
30M U.S. adults suffer from diabetes and 93M from obesity, with associated medical costs of over $300B annually, necessitating an urgent need for novel treatments AgeX-BAT1 for Type II diabetes and obesity aims to return brown adipose tissue, also known as “brown” or “good” fat, back to levels
Ion GeneStudio™ S5 Demonstrates Generation of Consistent and Reproducible Results in Lung Cancer Studies ALAMEDA, Calif. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced its
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 2, 2019-- AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at Biotech Showcase , to be held January 7-9, 2019 in San
Results of Key R&D Validation Study expected in January ALAMEDA, Calif. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced that it has run all of the 700 samples required for its
ALAMEDA, Calif. , Nov. 30, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced that the Company will provide a corporate overview at the LD Micro 11 th Annual Main Event Investor
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 29, 2018-- AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and CEO Michael D. West , Ph.D.
Company’s Common Stock Listed Under Symbol “AGE” ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 29, 2018-- AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced today that its common stock is
Two Sites in the UK Currently Enrolling Patients FREMONT, Calif. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological
ALAMEDA, Calif. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced that the Company will provide a corporate overview at the Piper Jaffray 30 th Annual Health Care Conference
Transition to New Diagnostic Testing Platform Complete Prospective R&D Validation Study Results Expected by Late 2018 or Early 2019 Development Plan Remains On-Track, Targeting Commercial Availability in 2H 2019 Conference Call Today at 4:30 pm ET ALAMEDA, Calif. , Nov.
Clinical Programs Continue to Progress Recent Transactions with affiliate of Novo Nordisk Increased Cash-on-Hand and Reduced Annual Operating Expenses Recently Announced Definitive Merger Agreement with BioTime Creates Leading Cell Therapy Company FREMONT, Calif. , Nov.
ALAMEDA, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the third quarter ended September 30, 2018 , on
FREMONT, Calif. , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today
Meeting with Food and Drug Administration Remains on Track for End of 2018 FREMONT, Calif. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated
Initiates Algorithm Development Study to Establish Accuracy in Interpreting Assay Results On-Track for Pivotal R&D Validation Study Results by Approximately Year End, with Commercial Availability Planned for 2H 2019 ALAMEDA, Calif. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE
ALAMEDA, Calif. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett , President and Chief Executive Officer, will provide a corporate overview at the BIO
Transactions Provide Additional Cash to Advance Clinical Programs and Process Development while Reducing Fixed Overhead FREMONT, Calif. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to
FREMONT, Calif. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today
FREMONT, Calif. , Sept. 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today
Two Sites in the UK Currently Enrolling Patients FREMONT, Calif. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological
FREMONT, Calif. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today
Technology supports Company’s strategy for off-the-shelf (allogeneic) cell-based regenerative medicine products through the use of the HLA-G gene ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 16, 2018-- AgeX Therapeutics, Inc. , a subsidiary of BioTime, Inc.
-Encouraging Study Data Drives Continued Development of DetermaVu™ Lung Cancer Diagnostic Test- -Conference Call Today at 4:30 pm ET - ALAMEDA, Calif. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of
ALAMEDA, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the appointment of Albert P. Parker , a seasoned industry executive with over 25 years of
Company Progressing Neurology and Immunotherapy Clinical Programs Anticipates Achievement of Significant Execution Milestones in the Second Half of 2018 and Full Year 2019 to Advance the Development of its Platform Technologies Conference Call and Webcast Today, August 9 , at 5:00 p.m.
-Company to Request Formal Meeting with FDA Under RMAT Designation this Quarter to Discuss Next Phase of Development for OPC Program- FREMONT, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based
ALAMEDA, Calif. , July 30, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced today that it will release its financial and operating results for the second quarter of 2018, ended
ALAMEDA, Calif. , July 27, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, today announced that it has entered into definitive agreements with certain investors led by members of
FREMONT, Calif. , July 26, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today
- Current Readout Includes New Six Month Data for Cohort 5 and Aggregate Trial Data - - Results Continue to Demonstrate Favorable Safety Profile, Potential for Durable Cell Engraftment at the Injury Site and Improved Motor Function - - 12 Month Top-Line Readout from the Entire SCiStar Study
AST-OPC1 has Demonstrated Positive Safety Profile and Promising Signs of Efficacy in a Phase 1/2a Trial for Severe Spinal Cord Injury FREMONT, Calif. , July 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 11, 2018-- AgeX Therapeutics , Inc., a subsidiary of BioTime , Inc. (NYSE American: BTX), today announced that Chief Executive Officer Michael D. West , Ph.D., who also serves as Co-CEO of BioTime , will present at the conference Ending Age-Related Diseases:
FREMONT, Calif. , July 11, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today
- Results suggest improved performance of next-generation test - Study results support move to new diagnostic testing platform - Significant development work required to fully validate this recent progress ALAMEDA, Calif. , July 09, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX),
FREMONT, Calif. , June 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced
ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 11, 2018-- AgeX Therapeutics , Inc., a subsidiary of BioTime, Inc . (NYSE American: BTX), focused on prolonging healthspan through an understanding of the fundamental mechanisms of human aging, today announced that it has closed a $5 million equity
Bestselling financial writer and visionary joins AgeX Board as Company enters next phase of growth ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 5, 2018-- AgeX Therapeutics , Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX) focused on prolonging healthspan through an understanding of the
- AST-OPC1 Safety Profile Continues To Be Favorable - FREMONT, Calif. , June 05, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and
AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London ALAMEDA, Calif. --(BUSINESS WIRE)--May 17, 2018-- AgeX Therapeutics , Inc., a subsidiary of BioTime, Inc .
FREMONT, Calif. , May 16, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that
Conference Call Today at 4:30 pm ET ALAMEDA, Calif. , May 15, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported financial and operating results for the first quarter ended March 31, 2018 .
- AST-VAC2 Immunotherapy Program Prepares to Enter Clinic in Second Quarter of 2018 – - Conference Call and Webcast Today, May 9 , at 5:00 p.m. ET – FREMONT, Calif. , May 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing
ALAMEDA, Calif , May 08, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced today that it will release its financial and operating results for the first quarter of 2018, ended March
FREMONT, Calif. , May 03, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced
FREMONT, Calif. , May 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that
Grant of Approximately $386,000 Will Enable Company to Accelerate its Clinical Development Programs for the Treatment of Diseases of Aging ALAMEDA, Calif. --(BUSINESS WIRE)--May 2, 2018-- AgeX Therapeutics , Inc., a subsidiary of BioTime , Inc. (NYSE American: BTX), today announced the award of a
FREMONT, Calif. , April 27, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced
-Release of clinical grade lot of AST-VAC2 is key step in Cancer Research UK’s initiation of clinical study in Non-Small Cell Lung Cancer - FREMONT, Calif. , April 25, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing
ALAMEDA, Calif. , April 03, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX) today announced the appointment of Ronald Andrews, Jr. , an executive with over 30 years’ experience in the molecular diagnostics and genomics industries, to the Company’s Board of Directors.
Development of DetermaVu™ Remains on Track for Completion in 2018 -Conference Call Today at 4:30 pm ET - ALAMEDA, Calif. , April 02, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today
New biomarkers could assist in differentiating malignant from benign lung nodules for improved lung cancer diagnosis ALAMEDA, Calif. , April 02, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early
ALAMEDA, Calif. , April 02, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX) today announced that Cavan Redmond , a director of the Company since 2015, has been named Chairman of the Board of Directors. Alfred D. Kingsley , who has been Chairman since 2009 and was instrumental in
ALAMEDA, Calif. , March 29, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced today that it will release its financial and operating results for the fourth quarter and full year
ALAMEDA, Calif. , March 28, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, today announced that it has closed a private placement of its common stock with two of its current
- Achieved Meaningful Progress with Key Clinical Programs - - Anticipate Multiple Data Readouts from SCiStar Study in 2018 into First Quarter of 2019 - - Expect to Enroll First Subject in AST-VAC2 Randomized Clinical Trial in NSCLC in Second Quarter - - Conference Call and Webcast Today, March 15 ,
FREMONT, Calif. , March 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:ST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today
Company Anticipates Commercial Launch During 2018 ALAMEDA, Calif. , March 08, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today provided an update on the development and commercial
ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 1, 2018-- AgeX Therapeutics , Inc., a subsidiary of BioTime, Inc . (NYSE American: BTX) today announced that the company’s Chief Executive Officer Michael D. West , Ph.D. will participate at three upcoming conferences: the Mauldin Economics Strategic
FREMONT, Calif. , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing regenerative medicine therapeutics to treat neurological conditions associated with de-myelination and cellular immunotherapies to treat cancer,
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 18, 2018-- AgeX Therapeutics , Inc., a subsidiary of BioTime , Inc. (NYSE American: BTX), today announced that AgeX will present in a Plenary session, “Stem Cell Innovations That Will Change the World – Part 2,” at the World Stem Cell Summit ( WSCS ) on
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 5, 2018-- AgeX Therapeutics, Inc. , a subsidiary of BioTime, Inc . (NYSE American: BTX), today announced that it will present at Biotech Showcase , January 8-10, 2018 at the Hilton San Francisco Union Square . Michael D.
FREMONT, Calif. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field of regenerative medicine, today provided its 2018 milestones targets for its spinal cord injury and cancer immunotherapy programs after successfully
- Published in the peer-reviewed journal Oncotarget – - Potential applications in scarless tissue regeneration, cancer, and aging - ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 2, 2018-- AgeX Therapeutics, Inc. ( AgeX ), a subsidiary of BioTime, Inc . (NYSE American: BTX), today announced a
FREMONT, Calif. , Dec. 19, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced enrollment and dosing of the last subject in the Company’s SCiStar Phase 1/2a clinical study of AST-OPC1 in motor
Study Results in Encouraging AUC Score of .935 ALAMEDA, Calif. , Dec. 07, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today presented positive data from its most recent breast cancer
Conference Theme is “The Path Forward for Regenerative Medicine: Traversing the Lab to the Patient” ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 4, 2017-- AgeX Therapeutics, Inc. ( AgeX ), a subsidiary of BioTime, Inc . (NYSE American: BTX) announced today that Chief Executive Officer Michael D.
Poster Presentation on December, 7, 2017, at 7:00 am CT ALAMEDA, Calif. , Dec. 01, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, will present data from its most recent breast cancer
ALAMEDA, Calif. , Nov. 29, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that it has initiated a search for a new independent member of its Board of Directors (the “Board”) to fill the
ALAMEDA, Calif. , Nov. 27, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett , President and Chief Executive Officer, and Mitch Levine , Chief Financial
FREMONT, Calif. , Nov. 16, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Michael Mulroy , President and Chief Executive Officer, will present at the Piper Jaffray Healthcare
ALAMEDA, Calif. , Nov. 15, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that Mitch Levine has been appointed Chief Financial Officer, effective November 15, 2017 .
- Continues to execute on key clinical programs and streamline cost structure - - Conference call and webcast today, November 14 , at 4:30 p.m. ET - FREMONT, Calif. , Nov. 14, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field
-Conference Call Today at 4:30 pm ET- ALAMEDA, Calif. , Nov. 14, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported financial results for the quarter ended September 30, 2017 , and provided an
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 8, 2017-- AgeX Therapeutics, Inc. ( AgeX ), a subsidiary of BioTime, Inc . (NYSE American: BTX) announced today that VP of New Scientific Discovery Aubrey de Grey, Ph.D. is participating on a panel at the FT Global Pharmaceutical and Biotechnology Conference
ALAMEDA, Calif. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended September 30, 2017 ,
FREMONT, Calif. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release third quarter 2017 financial and operational results on Tuesday, November 14, 2017
ALAMEDA, Calif.--(BUSINESS WIRE)-- AgeX ), a subsidiary of BioTime, Inc . (NYSE American: BTX), announced today that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, is giving an interview as part of The Economist magazine's conference, " type="text"
FREMONT, Calif. , Oct. 19, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company focused on the field of regenerative medicine, today announced that it closed its previously announced registered direct offering of an aggregate of four million shares of
FREMONT, Calif. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company focused on the field of regenerative medicine, today announced that it entered into a securities purchase agreement with certain institutional investors in connection with
67% of Cohort 2 subjects have recovered two or more motor levels on at least one side through 12 months Cohort 2 (AIS-A 10 million cells) motor level recovery vs. comparators AST-OPC1 receives Regenerative Medicine Advanced Therapy (RMAT) designation from FDA FREMONT, Calif., Oct.
DetermaVu™ Launch Planned for Fourth Quarter 2017 ALAMEDA, Calif. , Sept. 27, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive, blood-based liquid biopsy tests to assist in the early detection of cancer, announced today that its CLIA laboratory
Industry News Supports Development of First-in-Class Allogeneic Cancer Immunotherapy FREMONT, Calif. , Sept. 26, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the Medicines and
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 25, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, announced today that its Board of Directors has approved a distribution of some or all
FREMONT, Calif. , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the ongoing SCiStar Phase 1/2a study of AST-OPC1 in acute spinal cord injury will continue as planned,
ALAMEDA, CA – September 21, 2017---AgeX Therapeutics, Inc. ( AgeX ), a subsidiary of BioTime, Inc . (NYSE American: BTX), announces that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, is participating in a fireside chat at Cell & Gene Therapy CEO on Monday,
DetermaVu™ Launch On-Track for Fourth Quarter 2017 ALAMEDA, Calif. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests to assist in the early detection of cancer, announced today positive final results
Poster Presentation on December 7, 2017, at 7:00 am CT ALAMEDA, Calif. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced that data from its most recent breast
ALAMEDA, Calif. , Sept. 07, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that its clinical laboratory facility located in Alameda, California , has received Clinical Laboratory
FREMONT, Calif. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that members of the Company’s management team will be presenting at two upcoming investor conferences in
ALAMEDA, Calif. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE AMERICAN:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that Michael G. Vicari has been appointed to the newly created position of Vice President of Sales. Mr.
Data is Consistent with Early Data Read-Outs from Ongoing SCIStar Phase 1/2a Clinical Trial FREMONT, Calif. , Aug. 30, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced the publication of a
FREMONT, Calif. , Aug. 23, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Washington University School of Medicine in St. Louis, MO , has been added as a clinical site in the
• BioTime saving approximately $5 million annually on programs now in AgeX ALAMEDA, Calif.--( BUSINESS WIRE )-- AgeX Therapeutics, Inc. ( AgeX ), a subsidiary of BioTime, Inc . (NYSE American: BTX), announced today that it has closed its round of equity financing, raising net proceeds of $10
- Achieved meaningful progress with key clinical programs; multiple milestones anticipated during remainder of 2017- - Conference Call and Webcast Today, August 14 , at 4:30 p.m. ET - FREMONT, Calif. , Aug. 14, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc.
- Introduces Lung Cancer Diagnostic Branding- -Conference Call Today at 4:30 pm ET - ALAMEDA, Calif. , Aug. 14, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported the following developments:
Successful Production Run Provides Sufficient AST-VAC2 Supply to Initiate Clinical Study in Non-Small Cell Lung Cancer Expected to Begin in Second Half of 2017 FREMONT, Calif. , Aug. 14, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the
ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 9, 2017-- AgeX Therapeutics, Inc. ( AgeX ), a subsidiary of BioTime, Inc . (NYSE MKT:BTX), announced today that CEO Michael D. West , Ph.D., will deliver the keynote presentation at the RAAD Festival 2017 ( RAADfest ), a large annual gathering of life
Enrollment for entire SCiStar study expected to be completed by end-2017 FREMONT, Calif. , Aug. 09, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced enrollment and dosing of the first
FREMONT, Calif. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST) today announced that Lucas Lindner of Eden, Wisconsin , a quadriplegic patient who has regained functional use of his fingers, hands and lower arms after receiving the company’s investigational stem
ALAMEDA, Calif. , Aug. 07, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests to support the early detection of cancer, announced today that data from the Company’s latest confirmatory lung cancer diagnostic research have been accepted for a slide
FREMONT, Calif. , Aug. 07, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Mike Mulroy , President and Chief Executive Officer, will present at the Canaccord Genuity 2017 Growth
New sites include Thomas Jefferson University Hospital and UC San Diego Health FREMONT, Calif. , Aug. 03, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that two additional clinical sites
Leverages Intellectual Property Assets from the BioTime Group of Companies Relating to Cellular Immortality and Regenerative Biology Funding to Advance the Development of Products Targeting Large Markets Associated with Age-Related Disease ALAMEDA, Calif. --(BUSINESS WIRE)--Aug.
FREMONT, Calif. , July 31, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release second quarter 2017 financial and operational results on Monday, August 14, 2017
ALAMEDA, Calif. , July 26, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended June 30, 2017 , on Monday,
ALAMEDA, Calif. , July 25, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of $5.74 million through the cash exercise of 1,766,923 common stock purchase warrants. Each warrant was
- Abstract to Present Complete Study Findings Submitted to a Scientific Conference - - Final Stage of Development Commences- ALAMEDA, Calif. , July 24, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests to assist in the
Twenty patients have been enrolled in SCiStar study 20 million cell dose escalation cohort to inform future trial design Dosing fifth patient in this cohort triggers $1.5 million grant payment FREMONT, Calif. , July 17, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc.
World-Renowned Aging Researcher and Biomedical Gerontologist to Lead AgeX’s Research ALAMEDA, Calif. & MOUNTAIN VIEW, Calif. --(BUSINESS WIRE)--Jul. 13, 2017-- AgeX Therapeutics (“AgeX”), a subsidiary of BioTime , Inc. (NYSE MKT:BTX) with a focus on developing new therapies in the field of
First enrolled cohort comprised of patients with motor complete, sensory incomplete paralysis FREMONT, Calif. , July 12, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced completion of
Ability to enroll patients with second most common cervical spinal cord injury broadens eligible population for SCiStar study and future trials FREMONT, Calif. , July 10, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of
ALAMEDA, Calif. , June 26, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests for the early detection of cancer, has been added to the broad U.S. market Russell 3000® Index and the small-cap Russell 2000® Index as part of
ALAMEDA, Calif. , June 15, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it has successfully completed a follow on study of its breast cancer diagnostic test.
Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on at least one side FREMONT, Calif. , June 13, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field
ALAMEDA, Calif. , June 12, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests for the early detection of cancer, announced today that the Company is set to join the broad-market Russell 3000® Index at the conclusion of
FREMONT, Calif. , June 8, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that it will present new 9-month efficacy and safety data on those AIS-A patients treated with 10 million cells of
-Steve Cartt to transition out as President & CEO, remain on the Board of Directors- -Michael Mulroy appointed President & CEO effective June 26, 2017- -Katy Spink, Ph.D., promoted to Executive Vice President & COO- -Conference Call Today at 4:45pm ET- FREMONT, Calif.
- Continues Plans to Commercialize Lung Cancer Diagnostic Test in 2017 - - Conference Call Today at 4:30 PM Eastern Daylight Time - ALAMEDA, Calif. , May 22, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests for the
-Continued positive interim efficacy and safety results reported during the quarter; multiple data readouts on the efficacy and safety of AST-OPC1 anticipated during 2017- - Conference Call and Webcast Today, May 11, at 4:30 p.m. ET - FREMONT, Calif. , May 11, 2017 /PRNewswire/ -- Asterias
-MRI scans are consistent with durable engraftment of AST-OPC1 cells in the damaged area of the spinal cord and show the potential of AST-OPC1 to reduce spinal cord tissue deterioration after severe spinal cord injury- -These disease-modifying aspects of AST-OPC1 may carry long term benefits
ALAMEDA, Calif. , May 09, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that William Haack , Vice President of Market Access, will address the Next Generation Dx Summit 2017 on successful
FREMONT, Calif. , May 4, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release first quarter 2017 financial and operational results on Thursday, May 11, 2017 after the
ALAMEDA, Calif. , May 04, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based tests to aid in the early detection of cancer, today announced that a Medical Advisory Committee of lung cancer specialists has been established to provide guidance
FREMONT, Calif. , May 3, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that data from its AST-OPC1 clinical program for severe cervical spinal cord injury will be presented during the
Expects to Report Results of 300 Patient R&D Validation Study on May 22, 2017 Conference Call Scheduled for May 22, 2017 at 4:30pm ET ALAMEDA, Calif. , April 28, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests to aid in the early
-57% of AML patients treated with AST-VAC1, including high-risk patients, had prolonged relapse-free survival- FREMONT, Calif. , April 26, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today
FREMONT, Calif. , April 25, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) today announced that following a regularly scheduled interim review of safety data from its SCiStar Phase 1/2a clinical trial of AST-OPC1 for acute spinal cord injury, the study's Data Monitoring
Objective is to quickly establish leadership in the emerging biotechnology field of Aging through pluripotency and iTR ™ assets BioTime continues execution of corporate simplification strategy while remaining focused on Ophthalmology, Aesthetics and Therapeutics Delivery ALAMEDA, Calif.
- Recent clinical trial results highlight the potential for AST-OPC1 to help patients with complete paralysis recover arm, hand and finger function - - Company resources, improved significantly from a year ago, are now primarily focused on developing AST-OPC1 for the treatment of cervical spinal
Achieving Certification is Key Step for Planned Commercial Launch in the Second Half of 2017 ALAMEDA, Calif. , March 21, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests to aid in the early detection of cancer, has submitted its
-Newly reported data on sixth and final patient in cohort further confirms previously announced improvements in hand and arm function following dosing- FREMONT, Calif. , March 21, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of
FREMONT, Calif. , March 7, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that it will release fourth quarter and full year 2016 financial and operational results on Tuesday, March 28, 2017
Data from the Study Exceed Levels Believed Necessary for a Commercially Successful Test Conference Call Scheduled for Today at 4:30 PM ET ALAMEDA, Calif. , March 06, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests to aid in the
ALAMEDA, Calif. , March 01, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett , Chief Executive Officer, is scheduled to present an overview of the company and its
Enters into New Credit Facility with Silicon Valley Bank Conference Call Scheduled for Monday, March 6, 2017 at 4:30 PM ET ALAMEDA, Calif. , Feb. 27, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive, ”liquid biopsy” tests to aid in the early detection
Completes Sample Collection and Processing for the 300-Patient Study of its Lung Cancer Diagnostic Test ALAMEDA, Calif. , Feb. 21, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of
ALAMEDA, Calif. , Feb. 13, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett , Chief Executive Officer, is scheduled to present an overview of the company and its
- Warrant extension follows positive recent update on further motor function improvements observed in SCiStar study patients dosed with AST-OPC1 - - Cash position significantly improved from the same time last year - FREMONT, Calif. , Feb. 3, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc.
ALAMEDA, Calif. , Jan. 27, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that the Biotechnology Innovation Organization (BIO) has recognized OncoCyte Corporation as the Buzz of BIO winner in the
-Management to discuss results on conference call today at 5:00 p.m. Eastern / 2:00 p.m. Pacific- -SCiStar lead investigator Richard Fessler, MD, and John Steeves, Ph.D., Co-Chair of the Spinal Cord Outcomes Partnership Endeavor (SCOPE), will join Asterias management on the call- FREMONT, Calif.
ALAMEDA, Calif. , Jan. 24, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that its abstract on interim data from the Company’s lung cancer diagnostic test study has been selected for presentation in
Breast Cancer Test Development Three to Six Months Ahead of Schedule; Commercial Launch Possible in Mid to Late 2018 Lung Cancer Test Development Two to Three Months Behind Schedule; Commercial Launch Planned for Second Half of 2017 ALAMEDA, Calif. , Jan.
FREMONT, Calif. , Nov. 17, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced the appointment of Ryan Chavez to the position of Chief Financial Officer. In his expanded role, Mr.
-Study enrollment has recently accelerated, with three patients dosed in past week- -Achievement of enrollment milestone meets requirement for an additional $2.5 million grant payment to Asterias from the California Institute for Regenerative Medicine- -SCiStar investigator and patient will discuss
Study results in encouraging AUC ROC score of .92, follow up study underway ALAMEDA, Calif. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, provided a summary of the data from its breast cancer
Currently Processing Samples and Analyzing Results in its Lung Cancer Test Study; Continues to Project a Completion Date in Late December Conference Call to Discuss the Results at 5:00 p.m. ET ALAMEDA, Calif. , Nov. 10, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of
ALAMEDA, Calif. , Nov. 08, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based tests for the early detection of cancer, today announced that Lyndal Hesterberg , Ph.D. has been promoted to Senior Vice President, Research and Development, a
-Complete cervical spinal cord injury patient (AIS-A) has for the first time received maximum 20 million cell dose of AST-OPC1- -Enrollment and dosing of patients with incomplete cervical spinal cord injuries (AIS-B) continues; second AIS-B patient recently dosed with 10 million cells- FREMONT,
-SCiSTAR Investigator and Patient Will Join Call to Discuss Experiences with AST-OPC1- FREMONT, Calif. , Nov. 4, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that it will release third
ALAMEDA, Calif. , Nov. 02, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended September 30, 2016 on
ALAMEDA, Calif. , Nov. 02, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended September 30, 2016 on Thursday,
ALAMEDA, Calif. , Oct. 24, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based tests for the detection of cancer, today announced that it will be sponsoring a symposium at the American College of Chest Physician’s 2016 CHEST Annual Meeting,
LifeMap Solutions to participate in annual Medidata Symposium, showcasing demo app that studies the effects of caffeine consumption with attendees SAN JOSE, Calif. --(BUSINESS WIRE)--Oct. 18, 2016-- LifeMap Solutions, the digital health subsidiary of BioTime, Inc.
ALAMEDA, Calif. , Oct. 17, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based tests for the early detection of cancer, and The Wistar Institute , an international biomedical research leader in cancer, immunology and infectious diseases,
ALAMEDA, Calif. , Oct. 14, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett , Chief Executive Officer, is scheduled to present an overview of the Company and its progress at
-First dosing in SCiSTAR study of an AIS-B patient, characterized as having complete loss of movement while still retaining some sensory function below the cervical injury site- -Patient received 10 million cell dose of AST-OPC1- FREMONT, Calif. , Sept.
ALAMEDA, Calif. , Sept. 20, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett , Chief Executive Officer, is scheduled to present an overview of the Company and its progress at
-Asterias to Host Conference Call to Discuss Data on September 14, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Pacific- FREMONT, Calif. , Sept. 7, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), today announced that Edward Wirth , MD, PhD, Chief Medical Officer, will present interim
-Data Monitoring Committee (DMC) concludes that the favorable safety profile observed in the study supports plan for significant dose increase- -Newly enrolled complete cervical spinal cord injury patients will now receive the highest AST-OPC1 dose of 20 million cells- FREMONT, Calif. , Aug.
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 15, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its affiliate, Asterias Biotherapeutics , announced positive interim efficacy data from the AST-OPC1
-Cohort of SCiSTAR trial patients with complete cervical spinal cord injuries reaches the targeted 6-12 month efficacy endpoint within 3 months- -Dose response based on number of AST-OPC1 cells administered appears to be emerging- -Asterias to Host Conference Call Today at 4:30pm ET to Discuss
FREMONT, Calif. , Sept. 13, 2016 /PRNewswire/ -- Asterias Biotherapeutics (NYSE MKT: AST) announced today that Charles Y. Liu , MD, PhD, Director, USC Neurorestoration Center and investigator on the AST-OPC1 SCiSTAR Phase 1/2a clinical study in complete cervical spinal cord injury patients, will
FREMONT, Calif. , Sept. 12, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, announced that Steve Cartt , President and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual
Poster Presentation on December 9, 2016 at 5:00pm CT ALAMEDA, Calif. , Sept. 08, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that its breast cancer abstract has been selected for presentation in
-Asterias to Host Conference Call to Discuss Data on September 14, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Pacific- FREMONT, Calif. , Sept. 7, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), today announced that Edward Wirth , MD, PhD, Chief Medical Officer, will present interim
ALAMEDA, Calif. , Sept. 07, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett , Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the
-Data Monitoring Committee (DMC) concludes that the favorable safety profile observed in the study supports plan for significant dose increase- -Newly enrolled complete cervical spinal cord injury patients will now receive the highest AST-OPC1 dose of 20 million cells- FREMONT, Calif. , Aug.
Experienced Senior Executive with Track Record of Consistently and Rapidly Building Shareholder Value at Several Companies Makes Equity Investment in OncoCyte ALAMEDA, Calif. , Aug. 29, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood and urine
Net Proceeds to be Used to Continue R&D of Non-Invasive Cancer Diagnostics Tests and CLIA Compliant Laboratory Build-Out ALAMEDA, Calif. , Aug. 29, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer,
FREMONT, Calif. , Aug. 15, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today reported financial results for the second quarter ended June 30,
FREMONT, Calif. , Aug. 1, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that it will release second quarter financial and operating
ALAMEDA, Calif. , July 27, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, and The Wistar Institute , an international biomedical research leader in cancer, immunology and infectious diseases,
ALAMEDA, Calif. , July 21, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended June 30, 2016 on Thursday,
FREMONT, Calif. , July 18, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that the company has appointed Ryan Chavez as Executive Vice
- Expects to Announce Six-Month Results From This First Efficacy Cohort in January 2017- -Patient Motor Function Improvements Observed in Earlier Very Low Dose Safety Cohort- FREMONT, Calif. , July 12, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc.
New York, NY – June 28, 2016 /Press Release/ –– Mount Sinai Health System (MSHS) today announced the launch of a new mobile application for patients called MountSinaiNY. Developed by Mount Sinai’s Department of Information Technology , MountSinaiNY will serve as a one-touch patient experience,
-Oral presentation to review development of AST-OPC1 for spinal cord injury- -Panel discussion to focus on development of pluripotent stem cell therapies- FREMONT, Calif. , June 21, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three
ALAMEDA, Calif. , June 06, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, is presenting data today from a bladder cancer study featured as a poster and also highlighted during a live panel discussion during
-Data Included in Newly Submitted Patent Application for AST-OPC1- FREMONT, Calif. , May 24, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today
FREMONT, Calif. , May 23, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, announced today the closing of the exercise of the over-allotment option
Positive New Data to be Featured in a Poster Discussion ALAMEDA, Calif. , May 19, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT: OCX), a developer of novel, non-invasive tests for the early detection of cancer, released today the abstract of data from a bladder cancer study that will be
Conference Call to Discuss the Results at 5 p.m. ET ALAMEDA, Calif. , May 18, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, today reported its financial results for the quarter ended March 31,
-FDA Clears Expansion of AST-OPC1 Clinical Trial in Spinal Cord Injury- -Capital Resources Now in Place to Fund AST-OPC1 Clinical Trial Expansion and Continue Progress on Cancer Immunotherapy Programs- -Conference Call and Webcast Today, May 16, at 4:30 p.m. ET- FREMONT, Calif.
FREMONT, Calif. , May 13, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, announced today the closing of its previously announced underwritten public
ALAMEDA, Calif. , May 12, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended March 31, 2016 on Wednesday,
FREMONT, Calif. , May 11, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that it will release first quarter financial and operating
FREMONT, Calif. , May 10, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced the pricing of an underwritten public offering
FREMONT, Calif. , May 9, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that it intends to offer shares of its common stock and
New isolated cell line has the potential to address a critical unmet medical need for patients suffering from ischemic vascular disease ALAMEDA, Calif.--(BUSINESS WIRE) -- May 6, 2016 -- ReCyte Therapeutics, a subsidiary of BioTime, Inc., a clinical-stage regenerative medicine company with a focus
FREMONT, Calif. , May 2, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that clinical data from its AST-VAC1 (antigen-presenting
FREMONT, Calif. , April 28, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced the appointment of Howard I.
FREMONT, Calif. , April 26, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that Katharine Spink , Ph.D., Chief Operating Officer, will
Digital health solutions provider makes its ResearchKit and CareKit app expertise available to research institutions and health companies worldwide to advance insights into human health SAN JOSE, Calif. --(BUSINESS WIRE)--Apr. 25, 2016-- LifeMap Solutions, the digital health subsidiary of BioTime,
Live Panel Discussion on June 6, 2016 at 4:45pm CT ALAMEDA, Calif. , April 21, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that its bladder cancer abstract has been selected for
Will Present on Novel Strategies for the Production of Diverse Pluripotent Stem Cell Types for Drug Discovery ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 5, 2016-- BioTime, Inc. (NYSE MKT: BTX) today announced that Co-Chief Executive Officer Michael D. West , Ph.D.
FREMONT, Calif. , March 31, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Board of Directors has set the record date for its distribution of 3,320,916 warrants to holders
Conference Call and Webcast Today, March 29, at 4:30 p.m. ET FREMONT, Calif. , March 29, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today reported financial results for the fourth quarter and
FREMONT, Calif. , March 23, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release fourth quarter and full year 2015 financial and operating results on Tuesday, March
-- Don M. Bailey Appointed to Board of Directors and Named Chairman -- FREMONT, Calif. , Feb. 29, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) today announced the appointment of pharmaceutical industry veteran Stephen L. Cartt as President and Chief Executive Officer and
- Provides Direction for Late-Stage Development of AST-VAC1 in Acute Myeloid Leukemia - FREMONT, Calif. , Feb. 24, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE:AST) today announced the successful completion of an End-of-Phase 2 meeting with the U.S.
FREMONT, Calif. , Feb. 16, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today simplified its capital structure through the previously announced Asset Swap with BioTime, Inc.
FREMONT, Calif. , Feb. 4, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced receipt of Orphan Drug Designation from the U.S. Food and Drug Administration ( FDA ) for its product
FREMONT, Calif. , Feb. 2, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced Katy Spink , Chief Operating Officer, will present at the 18 th Annual BIO CEO & Investor Conference on
Exclusive Rights to Commercialize Biomarker Assay Follows Years of Positive Collaboration on Lung Cancer Diagnostic Test ALAMEDA, Calif. and PHILADELPHIA, Jan. 27, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT: OCX), a developer of novel, non-invasive blood based tests for the early
FREMONT, Calif. , Jan. 21, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), announced that it has completed the transfer of its manufacturing processes to produce AST-VAC2 to Cancer Research UK . AST-VAC2 is an innovative immunotherapy product that contains mature dendritic
ALAMEDA, Calif. , January 20, 2016 – LifeMap Sciences, Inc. (“ LifeMap ”), a life sciences technology company and subsidiary of BioTime , Inc., announced today the market launch of TGex™ ( Translational Genomics Expert ), an integrated next-generation genomic sequencing (NGS) analysis platform.
FREMONT, Calif. , Jan. 6, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that Pedro Lichtinger , President and CEO of Asterias, will present at the Biotech Showcase™ 2016 Conference
Company’s Common Stock Listed Under the Symbol "OCX" beginning January 4, 2016 The Company Will Publish an Introductory Investor Webcast January 5, 2016 at 4 p.m. ET OncoCyte Scheduled to Ring the NYSE Opening Bell on Wednesday, January 6, 2016 ALAMEDA, Calif., Jan.
Dr. Last Brings Over 30 Years of Corporate Strategy Experience to Liquid Biopsy Diagnostics Company ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 23, 2015-- OncoCyte Corporation (“OncoCyte”), a company focused on non-invasive cancer diagnostics, announced the appointment of Dr. Andrew J.
LifeMap’s first enterprise customer SuperCare Health to deploy customized COPD Navigator app with enhanced features, SuperCare iBreathe, to patients SAN JOSE, Calif. --(BUSINESS WIRE)--Dec. 3, 2015-- LifeMap Solutions, a digital-health subsidiary of BioTime, Inc.
Agreement strengthens LifeMap Sciences position in the NGS oncology market and provides LifeMap users with the option to access annotated cancer variants, as well as approved drugs and clinical trials related to a subject’s sequence information . ALAMEDA, Calif.
SAN JOSE, Calif.--(BUSINESS WIRE)-- Nov. 24, 2015--LifeMap Solutions, a subsidiary of BioTime, Inc., today announced the appointment of Robert W. Peabody as Chief Financial Officer. LifeMap is a technology pioneer, and an emerging provider of digital mobile health products, including ResearchKit
Conference Call and Webcast Today, November 9, at 4:30 p.m. ET MENLO PARK, Calif. , Nov. 9, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today reported financial and operating results for the
In the news release, Asterias Biotherapeutics to Report Third Quarter Results on November 9, 2015 , issued 05-Nov-2015 by Asterias Biotherapeutics, Inc. over PR Newswire, we are advised by the company that the webcast phone numbers and passcodes were incorrect, as originally issued inadvertently.
MENLO PARK, Calif. , Nov. 5, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release third quarter financial and operating results on Monday, November 9, 2015 after
LifeMap’s VarElect, The NGS Phenotyper , is now integrated into Lab7 ESP DNA sequence analysis, outputs and reports Lab7 ESP users can leverage VarElect ’s integrated features to rapidly identify causal mutations and examine related biological evidence ALAMEDA, Calif. & AUSTIN, Tex.
Executive Brings Proven Executive Leadership and Financial Acumen to Asterias MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced the appointment of Georgia
No Serious Adverse Events Reported with Initial AST-OPC1 Dose First Patient in Initial Dose Cohort Shows Neurological Improvement MENLO PARK, Calif. , Oct. 20, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative
MENLO PARK, Calif. , Oct. 13, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), has signed an agreement with the UK -based Cell Therapy Catapult to advance development of large scale manufacturing processes for AST-VAC2, Asterias' allogeneic dendritic cell immunotherapy.
MENLO PARK, Calif. , Oct. 12, 2015 /PRNewswire/ -- Jane S. Lebkowski, Ph.D., President of R&D and Chief Scientific Officer of Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, will participate in a BioPharma Dealmakers
ALAMEDA, Calif. , October 8, 2015 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today that its next generation sequencing (“NGS”) analysis and interpretation tools, VarElect ( http://varelect.genecards.org ), the NGS phenotyper, and GeneAnalytics ™ (
MENLO PARK, Calif. , Oct. 5, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Jane Lebkowski , Ph.D., President Research and Development and Chief Scientific Officer, will
Agreements Provide for the Development of an Innovative Cell Therapy Product for Bone Grafting in Orthopedic Unmet Needs Heraeus Medical to Fund All Product Development and Commercial Sales and Marketing Efforts OrthoCyte Will Be Responsible for Product Development and Manufacturing HANAU, Germany
NEW YORK --(BUSINESS WIRE)--Sep. 29, 2015-- The Icahn School of Medicine at Mount Sinai and LifeMap Solutions, a digital-health subsidiary of BioTime, Inc. , today announced initial results and new clinical features for their free Asthma Health app . Released six months ago, the app enables
Former CEO of WebMD and Group President of Pfizer Brings Over 25 Years of Corporate Strategy Experience to Liquid Biopsy Diagnostics Company ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 14, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX) announced the appointment of Cavan Redmond as an independent member
MENLO PARK, Calif. , Sept. 9, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced the publication of a manuscript in Regenerative Medicine relating to AST-OPC1 (oligodendrocyte
Safety of the Injection Procedure Confirmed with No Reported Serious Adverse Events ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 31, 2015-- BioTime, Inc. (NYSE MKT: BTX) announced today that subsidiary Asterias Biotherapeutics, Inc. , a biotechnology company focused on the emerging field of regenerative
Safety of the Injection Procedure Confirmed with No Reported Serious Adverse Events MENLO PARK, Calif. , Aug. 31, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the third
MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that executives from the company will present at two investor conferences in the month of September.
Agreement provides for continued development of a liquid biopsy test designed to aid physicians in the early, non-invasive detection of lung cancer PHILADELPHIA & ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 18, 2015-- The Wistar Institute and BioTime, Inc.
Conference Call and Webcast Today, August 10, at 4:30 p.m. ET MENLO PARK, Calif. , Aug. 10, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today reported financial and operating results for the
MENLO PARK, Calif. , July 29, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release second quarter financial and operating results on Monday, August 10, 2015 after the
-- Appointment Brings 30 Years of Strategic Advisory and Capital Markets Experience -- OncoCyte is Advancing Three Non-invasive Cancer Diagnostics Through Clinical Trials ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 15, 2015-- OncoCyte Corporation , a cancer diagnostics company and a member of the
The New GeneCards ® Powers LifeMap’s NGS Analysis and Interpretation Platform Enables Rapid Integration with Partners in the NGS Storage, Analysis and Interpretation Markets and Will Allow for Partnering Opportunities New User Interface, Functionality and Application Programming Interface (“API”)
MENLO PARK, Calif. , June 30, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000®, Russell 3000®, Russell Global and Russell Microcap® indexes
-- Appointment Brings Commercial, Operational, and Financial Expertise from Several Companies, Including Genentech and Accenture -- Biotechnology and Diagnostics Industry Leader to Focus on Later Stages of Clinical Trials and Commercialization of Three Non-Invasive Cancer Diagnostic Products -- All
Final Determination of Index Inclusion to be Published on June 26th MENLO PARK, Calif. , June 15, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine is included in the preliminary list of additions to
MENLO PARK, Calif. , June 8, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the first patient was successfully dosed at the Atlanta -based Shepherd Center in a Phase 1/2a
Data Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting Management to Host Conference Call and Webcast to Discuss AST-VAC1 Development Strategy on Wednesday, June 3, 2015, at 4:30 p.m. ET MENLO PARK, Calif. , June 1, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc.
MENLO PARK, Calif. , May 26, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that all outstanding common share purchase warrants originally issued in June 2014 were exercised prior
Data Presented at the 2015 American Thoracic Society International Conference ALAMEDA, Calif. --(BUSINESS WIRE)--May 19, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced the presentation of positive interim clinical results demonstrating the high level of
- Capital to fund further development and commercialization efforts of cancer diagnostic tests by BioTime subsidiary - ALAMEDA, Calif. --(BUSINESS WIRE)--May 14, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has received a new round of
Data to be Featured in Oral Presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting MENLO PARK, Calif. , May 14, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today
MENLO PARK, Calif. , May 7, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced the promotion of Edward D. Wirth, III , M.D., Ph.D., to the newly created role of Chief Medical Officer.
Conference Call and Webcast Today, May 7, at 4:30 p.m. ET Asterias to Host Investor Meeting Tomorrow, May 8, to Review AST-OPC1 Clinical Development Strategy for Spinal Cord Injury MENLO PARK, Calif. , May 7, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc.
Dr. John Steeves, Co-Chair of Spinal Cord Outcomes Partnership Endeavor, to Discuss Clinical Foundations for Endpoints and Outcome Measures in Spinal Cord Injury Trials Webcast Scheduled at 9:30 a.m. ET on May 8, 2015 MENLO PARK, Calif. , May 6, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc.
MENLO PARK, Calif. , April 30, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release first quarter financial and operating results on Thursday, May 7, 2015 after the
MENLO PARK, Calif. , April 21, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the abstract describing long-term follow-up of patients with acute myelogenous leukemia (AML) from
Data Presented at American Association for Cancer Research 2015 Annual Meeting ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 20, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced initial data from a large, prospective clinical study that showed the potential of
MENLO PARK, Calif. , April 9, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger , President and Chief Executive Officer of Asterias, will present at the 14th
MENLO PARK, Calif. , April 6, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger , President and Chief Executive Officer of Asterias, will present at the 14th
App for Patients is First Component of Broader Chronic-Condition Platform that Integrates with “Smart” Inhaler Technology and Clinician Dashboard SAN JOSE, Calif. --(BUSINESS WIRE)--Mar. 31, 2015-- LifeMap Solutions, an emerging digital therapeutics provider and subsidiary of BioTime, Inc.
Data to be Presented at American Association for Cancer Research 2015 Annual Meeting ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 20, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced the online availability of abstracts providing human clinical data
MENLO PARK, Calif. , March 18, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger , President and Chief Executive Officer of Asterias, will present at the Regen
AST-OPC1 Phase 1/2a Trial in Spinal Cord Injury Initiated in March Conference Call and Webcast Today, March 10, at 4:30 p.m. ET MENLO PARK, Calif. , March 10, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative
First-of-its-kind asthma study developed using ResearchKit framework NEW YORK --(BUSINESS WIRE)--Mar. 9, 2015-- The Icahn School of Medicine at Mount Sinai and LifeMap Solutions, a subsidiary of BioTime (NYSE MKT:BTX), today announced the launch of a large-scale medical research study that uses the
MENLO PARK, Calif. , March 5, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta -based Shepherd Center, one of the nation's top rehabilitation hospitals for spinal cord
In the news release, Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange , issued today by Asterias Biotherapeutics, Inc. over PR Newswire, we are advised by the company that the second paragraph, third sentence, should read "Of our two lead product candidates, AST-OPC1 for the
MENLO PARK, Calif. , March 4, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger , President and Chief Executive Officer, will ring The Opening Bell ® of the New
MENLO PARK, Calif. , March 2, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release fourth quarter and full year 2014 financial and operating results on Tuesday, March
LifeMap expands its next generation sequencing data analysis business, enhances Toldot’s next generation sequencing analysis services with LifeMap’s integrated knowledgebase and tools ALAMEDA, Calif., February 25, 2015 ― LifeMap Sciences, Inc. (LifeMap), a subsidiary of BioTime, Inc., announced
ALAMEDA, Calif., February 19, 2015 – LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc., announced today the release of GeneAnalytics ™ v1.1 , a powerful and easy-to-use gene set analysis tool that rapidly contextualizes RNAseq and microarray-derived gene expression patterns and function
MENLO PARK, Calif. , Feb. 10, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it has completed the previously announced underwritten public offering and
- BioTime subsidiary’s data collected from prospective clinical studies in bladder and breast cancer - ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 6, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that two abstracts, summarizing clinical studies of
MENLO PARK, Calif. , Feb. 5, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"), a leading biotechnology company in the emerging field of regenerative medicine, today announced today that it has priced an underwritten public offering of its common stock at a price
MENLO PARK, Calif. , Feb. 4, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it has commenced an underwritten public offering of its common stock. MLV & Co.
Advanced pathway analysis tool offered to LifeMap’s GeneCards’ users in more than 3,000 institutions in academia, research hospitals, and leading biopharma companies ALAMEDA, Calif., February 4, 2015 - LifeMap Sciences, Inc. (“LifeMap”), a subsidiary of BioTime, Inc., announced today a partnership
ALAMEDA, Calif. , January 15, 2015 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the commercial release of VarElect , a powerful, yet easy-to-use application for prioritizing gene variants resulting from next generation sequencing (“NGS”) experiments.
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 12, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that William Annett has been appointed to OncoCyte’s Board of Directors. Mr. Annett has extensive experience within the biotechnology and diagnostics industry,
MENLO PARK, Calif. , Jan. 7, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Katharine Spink , PhD, the Company's Chief Operating Officer, will present at the Biotech Showcase™
ALAMEDA, Calif. , December 11, 2014 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the release of MalaCards , Version 1.07. The new release is available at http://www.malacards.org/ . MalaCards is a database of human diseases and their annotations that is modeled on the
MENLO PARK, Calif. , Nov. 18, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that the Company's lead clinical program, AST-OPC1 (oligodendrocyte progenitor cells) for complete
MENLO PARK, Calif. , Nov. 17, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Jane S. Lebkowski , Ph.D., Asterias' President of Research and Development, will participate in a
MENLO PARK, Calif. , Nov. 10, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2014 .
IND cleared for Phase I/IIa dose escalation trial in patients with the dry form of age-related macular degeneration (AMD) called geographic atrophy (GA) No approved therapy exists for dry-AMD, the leading cause of visual impairment in an aging population in the US and other developed countries
MENLO PARK, Calif. , Oct. 31, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release third quarter financial and operating results on Monday, November 10, 2014 after
Provides for Immediate Release of Initial Grant Funds Menlo Park, Calif., October 20, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) announced today that the Company has signed a Notice of Grant Award (NGA) with the California Institute of Regenerative Medicine (CIRM),
Trading on NYSE MKT Expected to Begin on October 8, 2014 under Ticker Symbol AST MENLO PARK, Calif. , Oct. 6, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY) announced today that it received approval to list its Series A common stock on the NYSE MKT under the ticker symbol "AST."
IND filed for a Phase I/IIa dose escalation trial in patients with dry-AMD No approved therapy exists for dry-AMD, the leading cause of visual impairment in the aging population OpRegen ® will be the first preparation of xeno-free RPE cells to be evaluated clinically for dry-AMD ALAMEDA, Calif.
ALAMEDA, Calif. , October 6, 2014 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the recent release of MalaCards , Version 1.06. The new release is available at http://www.malacards.org/ , and features greatly improved gene-disease associations.
ALAMEDA, Calif., October 6, 2014 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the commercial release of GeneAnalytics 1.0 at www.geneanalytics.com . GeneAnalytics ™ is a powerful, yet easy to use, gene set analysis tool designed to help life scientists and biomedical
Additional Experts from Partner Icahn Institute at Mount Sinai Form Science Team ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 1, 2014-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary LifeMap Solutions, Inc. , a medical technology company, today announced significant additions to the LifeMap Solutions
Applies for Listing on the NYSE MKT MENLO PARK, Calif. --(BUSINESS WIRE)--Sep. 29, 2014-- Asterias Biotherapeutics, Inc. (OTCBB: ASTY) announced today that on October 1, 2014 the company will distribute 8,000,000 warrants to purchase common shares of BioTime, Inc.
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 19, 2014-- OncoCyte Corporation , a subsidiary of BioTime, Inc. (NYSE MKT: BTX), today announced that Chief Executive Officer Joseph Wagner , Ph.D. is scheduled to present at the inaugural BTIG Emerging Technologies in Healthcare Diagnostics Symposium being
ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--Sep. 17, 2014-- BioTime, Inc. (NYSE MKT: BTX), HBL Hadasit Bio-Holdings Ltd. ( Tel Aviv Stock Exchange : HDST) and Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has received the final results of a series of extensive
PanC-Dx ™ Markers to be Validated Using Pre-Diagnosis Patient Serum Samples Exclusively Provided by Abcodia ALAMEDA, Calif. & LONDON --(BUSINESS WIRE)--Sep. 15, 2014-- OncoCyte Corporation , a subsidiary of BioTime, Inc. (NYSE MKT: BTX), and Abcodia Ltd.
ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 11, 2014-- BioTime, Inc. (NYSE MKT: BTX) announced that its subsidiary Asterias Biotherapeutics, Inc. (OTCBB: ASTY) has reached an agreement with Cancer Research UK and Cancer Research Technology (CRT), the charity’s development and commercialization arm, to
-Conference Call and Webcast on September 12, 2014 at 8:30 a.m. ET, 5:30 a.m. PT- MENLO PARK, Calif. and LONDON , Sept. 11, 2014 /PRNewswire/ -- CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, have reached an agreement with Asterias
MENLO PARK, Calif. , Sept. 4, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY) announced today that its Board of Directors has set Monday, September 15, 2014 as the record date (the "Record Date") for determining holders of its Series A common stock entitled to receive BioTime,
Dose Escalation Clinical Trial to Test Initial Safety and Activity of AST-OPC1 in Patient Population with the First Indication Targeted for Product Registration FDA Clearance Triggers Definitive Contract Finalization with California Institute of Regenerative Medicine (CIRM) to Begin $14.3 Million
Dose Escalation Clinical Trial to Test Initial Safety and Activity of AST-OPC1 in Patient Population with the First Indication Targeted for Product Registration FDA Clearance Triggers Definitive Contract Finalization with California Institute of Regenerative Medicine (CIRM) to Begin $14.3 Million
- Wednesday, August 27, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT - MENLO PARK, Calif. , Aug. 25, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host an investor briefing
Welcomes New Shareholders Who Received Series A Shares from Geron Corporation Menlo Park, Calif., August 21, 2014 -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today the appointments of Andrew ("Andy") Arno
- PanC-Dx ™ Markers to be Tested on Over 1,000 Patient Samples from Urology Clinics Located Throughout United States - ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 31, 2014-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has expanded the clinical
- Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT - Menlo Park, Calif., July 24, 2014 -- Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host a live webcast of a presentation to
New release features powerful tools for registered members ALAMEDA, Calif. , July 10, 2014 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the release of GeneCards ® Version 3.12. The new release is available at www.genecards.org .
Capital infusion provides funding to advance Asterias’ therapeutic programs Substantially strengthens Asterias’ cash position ALAMEDA, Calif. & MENLO PARK, Calif. --(BUSINESS WIRE)--Jun. 17, 2014-- BioTime , Inc. (NYSE MKT: BTX) announced today that its subsidiary Asterias Biotherapeutics , Inc.
CEO Pedro Lichtinger purchases 200,000 shares of Asterias Series B common stock ALAMEDA, Calif. & MENLO PARK, Calif. --(BUSINESS WIRE)--Jun. 17, 2014-- BioTime , Inc. (NYSE MKT: BTX) today announced that on June 12, 2014 , Pedro Lichtinger , President and Chief Executive Officer of its subsidiary
Pharmaceutical and Biotechnology Industry Professional with 35 Years of Experience Extensive Track Record of Successful Drug Development and Commercialization Focused on Advancing Lead Product Candidates in Neurology and Cancer Immunotherapy ALAMEDA, Calif. & MENLO PARK, Calif.
Award Supports Phase 1/2a Dose Escalation Clinical Trial of AST-OPC1 in Cervical Spinal Cord Injury Funding Provides for the Expansion of AST-OPC1 Clinical Trial Originally Initiated by Geron Corporation into Target Population for Pivotal Studies MENLO PARK, Calif. & ALAMEDA, Calif.
MENLO PARK, Calif. & ALAMEDA, Calif. --(BUSINESS WIRE)--May 28, 2014-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Asterias Biotherapeutics, Inc. (“Asterias”), announced that Asterias has entered into a settlement agreement with ViaCyte, Inc. (“ViaCyte”) concerning certain litigation in the
- PanC-Dx ™ Markers to be Tested in Patient Samples Collected by Investigators at Weill-Cornell Medical Center - ALAMEDA, Calif. --(BUSINESS WIRE)--May 27, 2014-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has entered into a License Agreement
- No Serious Adverse Events Related to AST‑OPC1 Administration Reported in Phase 1 Trial of AST-OPC1, Originally Initiated by Geron Corporation, in Patients with Spinal Cord Injury - No Evidence of Antibody-Based or Cellular Immune Responses Menlo Park, Calif., May 22, 2014 -- Asterias
BioTime, Inc. Subsidiary Acquired Geron Corp’s Therapeutic Stem Cell Assets in Oct. 2013 MENLO PARK, Calif. & ALAMEDA, Calif. --(BUSINESS WIRE)--May 21, 2014-- Asterias Biotherapeutics, Inc. , a subsidiary of BioTime, Inc. (NYSE MKT: BTX) that is developing clinical-stage stem cell therapeutic
ALAMEDA, Calif. --(BUSINESS WIRE)--May 13, 2014-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Asterias Biotherapeutics, Inc. today announced that Jane S. Lebkowski , PhD, President, Research & Development of Asterias, will present at the 17th Annual Meeting of the American Society of Gene &
ALAMEDA, Calif. --(BUSINESS WIRE)--May 7, 2014-- BioTime, Inc. (NYSE MKT:BTX) announced today that its subsidiary LifeMap Sciences, Inc. , a technology leader in online biomedical information, has created LifeMap Solutions, Inc. , a medical technology startup focused on creating innovative mobile
ALAMEDA, Calif., March 13, 2014 – LifeMap Sciences, Inc. announced today the release of LifeMap Discovery ® version 1.6 ( discovery.lifemapsc.com ). LifeMap Discovery ® is a state-of-the-art roadmap of embryonic development and stem cell biology. The product integrates embryonic development and
ALAMEDA, Calif. , March 10, 2014 – LifeMap Sciences, Inc. announced today the release of MalaCards , Version 1.05. The new release is available at www.malacards.org . MalaCards is a database of human diseases and their annotations that is modeled on the architecture and richness of the popular
- PanC-Dx ™ Markers to be Tested Include Those Recently Awarded Patent Protection - ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 27, 2014-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has initiated clinical development of its bladder cancer
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 17, 2014-- LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of LifeMap Discovery ™ version 1.5 ( discovery.lifemapsc.com ) . LifeMap Discovery ™ is a state-of-the-art roadmap of embryonic development and stem
MENLO PARK, Calif. & ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 2, 2014-- Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) today announced that Asterias has executed a long term lease for a research, development and manufacturing facility to house all of its cell therapy product
ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--Dec. 23, 2013-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2014 of 6.1 million Shekels (approximately $1.74 million ) from Israel’s Office of the
New Release Features showcasing of gene-relevant scientific conferences ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 6, 2013-- LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards ® , Version 3.11.
MENLO PARK and ALAMEDA, Calif., December 2, 2013 – Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that Asterias has filed a registration statement with the Securities and Exchange Commission for an underwritten public offering of up to $15,000,000 of
MENLO PARK, Calif. & ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 28, 2013-- Asterias Biotherapeutics, Inc. , a majority-owned subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that it plans to file a registration statement with the Securities and Exchange Commission in November 2013 for an
- PanC-Dx TM Markers to be Tested in Multi-Center Lung Cancer Study Currently Underway - ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 15, 2013-- BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte has entered into a Sponsored Research Agreement and a
MENLO PARK, Calif. & ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 1, 2013-- Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) jointly announced today the closing of the transactions under the Asset Contribution Agreement (the “Agreement”) with Geron Corporation , previously announced on
ALAMEDA, Calif.--(BUSINESS WIRE)--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the release of MalaCards , Version 1.04. The new release is available at http://www.malacards.org . MalaCards is a new database of human diseases and their annotations that is modeled on the
- FSIP1 is one component of a panel of markers comprising PanC-Dx TM , a blood-based cancer screen - ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 5, 2013-- BioTime, Inc. (NYSE MKT: BTX) and BioTime’s subsidiary OncoCyte Corporation today announced the publication of a scientific report on the gene FSIP1
ALAMEDA, Calif., July 26, 2013 – LifeMap Sciences, Inc. announced today the release of LifeMap Discovery™ version 1.2 (discovery.lifemapsc.com) . LifeMap Discovery ™ is a state-of-the-art roadmap of embryonic development and stem cell biology. The product integrates embryonic development and stem
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 18, 2013-- LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that the LifeMap Discovery™ product has been documented in a published paper authored by LifeMap Sciences’ research and development team.
ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--May. 13, 2013-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences) today announced that Cell Cure Neurosciences has been awarded a grant of 5.34 million Shekels , approximately $1.5 million , for
New Release Features “Super-Pathways” and Collaboration with Lost Island Labs, Inc. ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 30, 2013-- LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards ® , Version 3.10.
Agreement will integrate critical sources of genetic and disease information into Appistry’s next-generation sequencing (“NGS”) reports for clinicians ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 23, 2013-- LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc.
ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 18, 2013-- LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that its MalaCards database has been recognized in a published paper by the Weizmann Institute of Science research group under the supervision of Prof.
- BioTime Subsidiary offers 100 select recombinant proteins in its BioReagents Portal - ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 10, 2013-- LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that it is now offering 100 selected ProSpec-Tany TechnoGene (ProSpec)
ALAMEDA, Calif., March 25, 2013 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of LifeMap Discovery ™ version 1.1 ( discovery.lifemapsc.com ). LifeMap Discovery™ is a key component in LifeMap’s integrated database suite, a discovery platform for
- Company describes new product plans aimed at further monetizing these assets - ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 11, 2013-- LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc. (NYSE MKT:BTX), announced today that according to Google Analytics, the Company’s databases have attracted over
Multi-center clinical study of a blood-based diagnostic test for the early detection of cancer planned for 2013 ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 31, 2013-- BioTime, Inc. (NYSE MKT: BTX) and BioTime’s subsidiary OncoCyte Corporation provided an update on the progress of development of PanC-Dx
Report shows the existence of ∼80,000 human non-redundant non-coding RNAs covering 71% of the human genome, slightly less than the ENCODE prediction of 80% ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 30, 2013-- LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc.
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 9, 2013-- LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of MalaCards version 1.02 on January 7 . The new release is available at www.malacards.org . MalaCards is a new database of human diseases and their
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 27, 2012-- LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the launch of LifeMap Discovery™ ( discovery.lifemapsc.com ), a state-of-the-art roadmap of embryonic development and stem cell biology.
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 20, 2012-- LifeMap Sciences, Inc. a subsidiary of BioTime, Inc. (NYSE MKT: BTX) announced today that it has signed a definitive distribution agreement with ProSpec-Tany TechnoGene Ltd. (ProSpec). In the beginning of 2013, LifeMap Sciences will be offering
ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 19, 2012-- LifeMap Sciences, Inc. , a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards ® , Version 3.09, on November 18, 2012 . The new release is available at www.genecards.org .
Adds senior executive with significant experience in developing cell-based orthopedic products ALAMEDA, Calif. --(BUSINESS WIRE)--Nov. 1, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OrthoCyte Corporation today announced the appointment of Francois Binette , PhD, as OrthoCyte’s Vice
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 23, 2012-- BioTime, Inc. (NYSE MKT: BTX) and LifeMap Sciences, Inc. announce the launch of MalaCards, a new database of human diseases that is based on their leading GeneCards ® platform. MalaCards ( www.malacards.org/ ) contains computerized “cards”
ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 19, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary, LifeMap Sciences, Inc. , today announced the appointment of Louis E. Silverman to LifeMap Sciences’ board of directors. Mr. Silverman is an experienced health care executive with board level and
ALAMEDA, Calif. & JERUSALEM --(BUSINESS WIRE)--Aug. 1, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2012 of 5.04 million Shekels (approximately $1.33 million ) from Israel’s Office of the
ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 26, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences, Inc. (“LifeMap”) today announced that LifeMap entered into a Share Exchange and Contribution Agreement with Alfred D. Kingsley and a company that he controls, Greenway Partners,
ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) announced today that David Warshawsky, Ph.D., CEO of BioTime's subsidiary LifeMap Sciences, Inc. will provide an update on product development at an investor meeting in New York City today. Dr.
ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) announced today that Steven Kessler, Ph.D., Vice President of Research at BioTime's subsidiary ReCyte Therapeutics, Inc. will provide an update on the development of reprogramming technologies and the generation of
- PanC-Dx on track for CE Marking in Europe by late 2014 - ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) announced today that Joseph Wagner, Ph.D., the CEO of BioTime's subsidiary OncoCyte Corporation and Karen B. Chapman, Ph.D., Director of Bioinformatics will
- Product development on track for IND filing during 2013 - ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) announced today that Charles S. Irving, Ph.D., the CEO of BioTime's subsidiary Cell Cure Neurosciences, Ltd. will provide an update on the development of
- An annual PanC-Dx TM blood test could be the future alternative to the mammogram as the frontline screening method for breast cancer - ALAMEDA, Calif. --(BUSINESS WIRE)--Mar. 22, 2012-- BioTime, Inc. (NYSE Amex: BTX) and BioTime’s subsidiary OncoCyte Corporation today provided a progress report
ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 21, 2011-- BioTime, Inc. (NYSE Amex: BTX) today announced agreements with USCN Life Science, Inc. (USCN) of Wuhan, China , granting BioTime an option to license USCN’s antibody-producing cell lines and certain related technology that may be used by BioTime
- A novel blood-based screening method for the early detection of many common human cancers such as those of the breast, colon, and lung - ALAMEDA, Calif., Dec 16, 2011 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) and BioTime's subsidiary OncoCyte Corporation today announced plans for the
Capital to be utilized in advancing the development of novel cancer diagnostic and therapeutic products BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced its majority-owned subsidiary OncoCyte Corporation
Database to promote the marketing of BioTime's research products BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has formed LifeMap Sciences, Inc., in collaboration with XenneX, Inc.
William P. Tew, Ph.D. Becomes Vice President, Business Development of BioTime and OrthoCyte BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the fields of stem cells, regenerative medicine and blood plasma volume expanders today announced it has
Acquisition to accelerate BioTime's development of tissue engineered therapeutic products and expand research product portfolio BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has
--Proprietary technology "paints" cells with peptides to target them to diseased tissues-- BioTime, Inc. (NYSE Amex:BTX) today announced that it has acquired substantially all the assets of Cell Targeting, Inc. (CTI), a Cleveland, Ohio-based biotechnology company conducting research in regenerative
$4 Million Equity Financing Company Plans Near-Term Commercialization of iPS Cell Banking Services that Reverse the Developmental Aging of Human Cells BioTime, Inc. (NYSE Amex:BTX) today announced a $4 million equity financing by its subsidiary, Embryome Sciences, Inc.
To Develop and Market OpRegen TM for the Treatment of Age-Related Macular Degeneration JERUSALEM & ALAMEDA, Calif., Oct 10, 2010 (BUSINESS WIRE) -- BioTime, Inc. (NYSE Amex:BTIM), Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange:HDST) jointly announced today that
JERUSALEM & ALAMEDA, Calif., Oct 10, 2010 (BUSINESS WIRE) -- BioTime, Inc. (NYSE Amex:BTIM), Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange:HDST) jointly announced today that Cell Cure will receive an equity investment of $7.1 million from BioTime, Teva
BioTime, Inc. (NYSE Amex:BTIM) announced that its subsidiary OncoCyte Corporation has completed the funding of the second tranche of a private equity offering through the sale of 3,000,000 shares of OncoCyte common stock for $2,000,000 to a private investor.
Agreement Provides Investor Option for an Additional $2 Million Investment Within Six Months BioTime, Inc. (OTCBB:BTIM) announced today that it has organized a new subsidiary, OncoCyte Corporation, for the purpose of developing novel therapeutics for the treatment of cancer based on stem cell
